Stack, J. et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201, 1007-1018

Imperial College London, Londinium, England, United Kingdom
Journal of Experimental Medicine (Impact Factor: 12.52). 04/2005; 201(6):1007-18. DOI: 10.1084/jem.20041442
Source: PubMed


Viral immune evasion strategies target key aspects of the host antiviral response. Recently, it has been recognized that Toll-like receptors (TLRs) have a role in innate defense against viruses. Here, we define the function of the vaccinia virus (VV) protein A46R and show it inhibits intracellular signalling by a range of TLRs. TLR signalling is triggered by homotypic interactions between the Toll-like-interleukin-1 resistance (TIR) domains of the receptors and adaptor molecules. A46R contains a TIR domain and is the only viral TIR domain-containing protein identified to date. We demonstrate that A46R targets the host TIR adaptors myeloid differentiation factor 88 (MyD88), MyD88 adaptor-like, TIR domain-containing adaptor inducing IFN-beta (TRIF), and the TRIF-related adaptor molecule and thereby interferes with downstream activation of mitogen-activated protein kinases and nuclear factor kappaB. TRIF mediates activation of interferon (IFN) regulatory factor 3 (IRF3) and induction of IFN-beta by TLR3 and TLR4 and suppresses VV replication in macrophages. Here, A46R disrupted TRIF-induced IRF3 activation and induction of the TRIF-dependent gene regulated on activation, normal T cell expressed and secreted. Furthermore, we show that A46R is functionally distinct from another described VV TLR inhibitor, A52R. Importantly, VV lacking the A46R gene was attenuated in a murine intranasal model, demonstrating the importance of A46R for VV virulence.

Download full-text


Available from: Martina Schroeder
  • Source
    • "Reserve (VACV) and VACV-A5L-EGFP (Carter et al., 2003) were used in this work. The anti-A46 antibody was a kind gift from Andrew Bowie (Stack et al., 2005), the anti-D8 antibody a kind gift from Geoffrey Smith (Parkinson and Smith, 1994). Other antibodies used were anti-RAB1A (ab97956, Abcam), anti-GM130 (610822, BD Pharmingen ), and anti-B5 (NR-556, BeiResources). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vaccinia virus (VACV) is a large double-stranded DNA virus with a complex cytoplasmic replication cycle that exploits numerous cellular proteins. This work characterises the role of a proviral cellular protein, the small GTPase RAB1A, in VACV replication. Using siRNA, we identified RAB1A as required for the production of extracellular enveloped virions (EEVs), but not intracellular mature virions (IMVs). Immunofluorescence and electron microscopy further refined the role of RAB1A as facilitating the wrapping of IMVs to become intracellular enveloped virions (IEVs). This is consistent with the known function of RAB1A in maintenance of ER to Golgi transport. VACV can therefore be added to the growing list of viruses which require RAB1A for optimal replication, highlighting this protein as a broadly proviral host factor. Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.
    Full-text · Article · Nov 2014 · Virology
  • Source
    • "Activation of the NFκB pathway through the IL-1R is prevented by A52R, A46R, and K7L (Bowie et al., 2000; Schroder et al., 2008). A46R binds the TIR-domain containing adapter proteins MyD88, TRIF, TIRAP, and TRAM, and prevents them from associating with the IL-1R (Bowie et al., 2000; Stack et al., 2005). A52R and K7 bind TRAF6 and IRAK2 to disrupt signaling complexes containing these proteins (Bowie et al., 2000; Graham et al., 2008; Harte et al., 2003; Schroder et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A notable feature of poxviruses is their ability to inhibit the antiviral response, including the nuclear factor kappa B (NFκB) pathway. NFκB is a transcription factor that is sequestered in the cytoplasm until cell stimulation, and relies on the SCF (Skp1, culllin-1, F-box) ubiquitin ligase to target its inhibitor, IκBα, for degradation. IκBα is recruited to the SCF by the F-box domain-containing protein βTrCP. Here, we show that ectromelia virus, the causative agent of mousepox, encodes four F-box-containing proteins, EVM002, EVM005, EVM154, and EVM165, all of which contain Ankyrin (Ank) domains. The Ank/F-box proteins inhibit NFκB nuclear translocation, and this inhibition is dependent on the F-box domain. We also demonstrate that EVM002, EVM005, EVM154, and EVM165 prevent IκBα degradation, suggesting that they target the SCF. This study identifies a new mechanism by which ectromelia virus inhibits NFκB.
    Full-text · Article · Sep 2014 · Virology
  • Source
    • "Detection of TRAF2, p84, A46, and D8 was carried out using direct infrared fluorescence (Li-Cor). Blots were treated with Odyssey blocking buffer (Li-Cor) before incubation with A46 (53), D8 (54), TRAF2 (Santa Cruz), p84 (GeneTex), or β-actin (AbCam) antibodies. Goat anti-rabbit IgG (H+L) DyLight 800 conjugate (Cell Signaling) and goat anti-mouse IgG (H+L) DyLight 680 conjugate (Cell Signaling) were used as secondary antibodies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor necrosis factor receptor (TNFR)-associated factor 2 (TRAF2) is a pivotal intracellular mediator of signaling pathways downstream of TNFR1 and -2 with known pro- and antiviral effects. We investigated its role in the replication of the prototype poxvirus vaccinia virus (VACV). Loss of TRAF2 expression, either through small interfering RNA treatment of HeLa cells or through genetic knockout in murine embryonic fibroblasts (MEFs), led to significant reductions in VACV growth following low-multiplicity infection. In single-cycle infections, there was delayed production of both early and late VACV proteins as well as accelerated virus-induced alterations to cell morphology, indicating that TRAF2 influences early stages of virus replication. Consistent with an early role, uncoating assays showed normal virus attachment but delayed virus entry in the absence of TRAF2. Although alterations to c-Jun N-terminal kinase (JNK) signaling were apparent in VACV-infected TRAF2−/− MEFs, treatment of wild-type cells with a JNK inhibitor did not affect virus entry. Instead, treatment with an inhibitor of endosomal acidification greatly reduced virus entry into TRAF2−/− MEFs, suggesting that VACV is reliant on the endosomal route of entry in the absence of TRAF2. Thus, TRAF2 is a proviral factor for VACV that plays a role in promoting efficient viral entry, most likely via the plasma membrane. IMPORTANCE Tumor necrosis factor receptor-associated factors (TRAFs) are key facilitators of intracellular signaling with roles in innate and adaptive immunity and stress responses. We have discovered that TRAF2 is a proviral factor in vaccinia virus replication in both HeLa cells and mouse embryonic fibroblasts and that its influence is exercised through promotion of efficient virus entry.
    Full-text · Article · Jan 2014 · Journal of Virology
Show more